Edgewise Therapeutics, Inc.
EWTX
Rank in Stocks
#4009
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Share Price
$37.82
Market Cap
$4.07B
Change (1 day)
1.69%
Change (1 year)
151.13%
Country
US
Trade Edgewise Therapeutics, Inc. (EWTX)
Category
Healthcare
Number of shares outstanding for Edgewise Therapeutics, Inc. (EWTX)
Number of shares outstanding as of June 2026: 107.67M
According to Edgewise Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 107.67M. At the end of December 2023 the company had 63.72M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Edgewise Therapeutics, Inc. (EWTX) from 2019 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 107.67M | 16.51% |
| 2024 | 92.41M | 45.02% |
| 2023 | 63.72M | 18.90% |
| 2022 | 53.59M | 8.27% |
| 2021 | 49.50M | 0.58% |
| 2020 | 49.22M | 0.00% |
| 2019 | 49.22M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 135.81% |
US
|
|
| 396.00M | 267.79% |
US
|
|
| 478.91M | 344.80% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -42.24% |
NL
|
